64 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis.
Merck Research Laboratories
Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
Syntrix Biosystems
Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Glaxosmithkline
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Broad Institute of Mit and Harvard
Structure-activity relationships of phomactin derivatives as platelet activating factor antagonists.
Sankyo
Synthesis of alkyl chain-modified ether lipids and evaluation of their in vitro cytotoxicity.
Laboratorios Menarini
Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
Pfizer
Novel antagonists of platelet-activating factor. 1. Synthesis and structure-activity relationships of benzodiazepine and benzazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
Pfizer
3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists.
Abbott Laboratories
Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
Universit£
Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
American Cyanamid
Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester.
Merck Research Laboratories
1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
Pfizer
Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
Takeda Chemical Industries
A 3D-QSAR study on ginkgolides and their analogues with comparative molecular field analysis.
Chinese Academy of Sciences
Cyclic ether acetal platelet activating factor (PAF) receptor antagonists II: imidazo[4,5-c]pyridyl derivatives
TBA
Cyclic ether acetal platelet activating factor (PAF) receptor antagonists I: 3-pyridyl derivatives
TBA
Synthesis and biological activity of the platelet-activating factor antagonist ()-trans-2-(3-methoxy-4-phenylsulfonylethoxy-5-n-propylsulfonylphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-671,284) and its analogs
TBA
Synthesis and biological activity of MK 287 (L-680,573): a potent, specific and orally active paf receptor antagonist
TBA
The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonists.
TBA
Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
Pfizer
Chemistry, biosynthesis and biological activity of terpenoids and meroterpenoids in bacteria and fungi isolated from different marine habitats.
Iranian Fisheries Science Research Institute
Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists.
Columbia University
Ginkgolide derivatives for photolabeling studies: preparation and pharmacological evaluation.
Columbia University
In vitro platelet-activating factor receptor binding inhibitory activity of pinusolide derivatives: a structure-activity study.
Seoul National University
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.
University of Virginia
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
Abbott Laboratories
Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
American Cyanamid
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
J. Uriach & CíA.
Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists.
Sandoz Research Institute
Antitumor activity of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines.
Sandoz Research Institute
Development of a novel series of trialkoxyaryl derivatives as specific and competitive antagonists of platelet activating factor.
Wellcome Research Laboratories
Pyrido[2,1-b]quinazolinecarboxamide derivatives as platelet activating factor antagonists.
Hoffmann-La Roche
Conformation and activity of tetrahydrofuran lignans and analogues as specific platelet activating factor antagonists.
TBA
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
Roche Research Center
Biphenylcarboxamide derivatives as antagonists of platelet-activating factor.
Roche Research Center
Propenyl carboxamide derivatives as antagonists of platelet activating factor.
Hoffmann-La Roche
Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2.
Roche Research Center
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
Roche Research Center
Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
Schering-Plough
4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.
J. Uriach & CíA.
Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.
Abbott Laboratories
Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2.
Kyowa Hakko Kogyo
SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
Sanofi-Synthelabo Recherche
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
Pudue Pharma Discovery Research
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
Sanofi Recherche
Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Merck Sharp & Dohme Research Laboratories